drugset / Trial / NCT02431325
A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV
Phase 2
Completed
32 enrolled
Massachusetts General Hospital
National Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collabRagon Institute of MGH, MIT and Harvard · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research study is to determine whether teduglutide can repair a "leaky" gut, decrease inflammation, and prevent or treat plaque, a build-up of fat and other materials in the blood vessels of the heart, in people with HIV. HIV disease is linked to inflammatory changes and leakiness of the gut. These changes or conditions may increase the risk of developing heart and blood vessel disease. The investigators believe teduglutide can help repair the gut barrier in people with HIV, leading to a decrease in inflammation and plaque in the blood vessels of the heart.
Timeline
- Start
- 2015-12
- Primary completion
- 2020-01-21
- Completion
- 2021-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teduglutide | Peptide | 0.05 mg/kg | Subcutaneous |